Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

12.31USD
18 Jan 2019
Change (% chg)

$0.01 (+0.08%)
Prev Close
$12.30
Open
$12.34
Day's High
$12.47
Day's Low
$12.05
Volume
636,642
Avg. Vol
883,815
52-wk High
$17.60
52-wk Low
$8.28

Select another date:

Mon, Aug 13 2018

Photo

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

UPDATE 1-Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Select another date: